Evidence map›Paper›PMID 39911259›Full record

ReviewInternational journal of nanomedicine2025

Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine.

Zahra Izadiyan, Misni Misran, Katayoon Kalantari, Thomas J Webster, Pooneh Kia, Noor Ashyfiyah Basrowi, Elisa Rasouli, Kamyar Shameli

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Green Extraction and Liposomal Encapsulation ofMolecules (Basel, Switzerland) · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zahra IzadiyanDepartment of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
Misni MisranDepartment of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
Katayoon KalantariDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA.
Thomas J WebsterBiomedical Engineering, Hebei University of Technology, Tianjin, People's Republic of China.ORCID 0000-0002-2028-5969
Pooneh KiaInstitute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.ORCID 0000-0003-0449-5402
Noor Ashyfiyah BasrowiDepartment of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
Elisa RasouliDepartment of Electrical and Electronics Engineering, Nanyang Technological University, Nanyang, Singapore.
Kamyar ShameliSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.ORCID 0000-0002-3955-4604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposomal nanomedicines have emerged as a pivotal approach for the treatment of various diseases, notably cancer and infectious diseases. This manuscript provides an in-depth review of recent advancements in liposomal formulations, highlighting their composition, targeted delivery strategies, and mechanisms of action. We explore the evolution of liposomal products currently in clinical trials, emphasizing their potential in addressing diverse medical challenges. The integration of immunotherapeutic agents within liposomes marks a paradigm shift, enabling the design of 'immuno-modulatory hubs' capable of orchestrating precise immune responses while facilitating theranostic applications. The recent COVID-19 pandemic has accelerated research in liposomal-based vaccines and antiviral therapies, underscoring the need for improved delivery mechanisms to overcome challenges like rapid clearance and organ toxicity. Furthermore, we discuss the potential of "smart" liposomes, which can respond to specific disease microenvironments, enhancing treatment efficacy and precision. The integration of artificial intelligence and machine learning in optimizing liposomal designs promises to revolutionize personalized medicine, paving the way for innovative strategies in disease detection and therapeutic interventions. This comprehensive review underscores the significance of ongoing research in liposomal technologies, with implications for future clinical applications and enhanced patient outcomes.

Indexed as

LiposomesNanomedicinePrecision MedicineCOVID-19Drug Delivery SystemsHumansImmunotherapyNeoplasmsSARS-CoV-2Liposomesactive targetingcancer therapyliposomesnano-carrierstargeted drug delivery

Identifiers

PMID39911259
PMCPMC11794392

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.